Statistics from Altmetric.com
Commentary on: Siegal DM, Curnette JT, Connolly SJ, et al. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24.
Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal agent for DOACs, idarucizumab recently received Food and Drug Administration approval as the reversal of the direct thrombin inhibitor, dabigatran. A reversal agent for the factor Xa-inhibitors, Andexanet Alfa is the subject of a recent Phase 3a trial and the core topic of this commentary.2
In a two-part, randomised, placebo-controlled study, healthy, older volunteers were established on 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. Andexanet alfa was then administered as a …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.